Form 8-K - Current report:
SEC Accession No. 0001104659-24-044325
Filing Date
2024-04-05
Accepted
2024-04-05 16:51:01
Documents
14
Period of Report
2024-04-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2411028d1_8k.htm   iXBRL 8-K 28654
2 EXHIBIT 99.1 tm2411028d1_ex99-1.htm EX-99.1 27105
  Complete submission text file 0001104659-24-044325.txt   237917

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rnaz-20240403.xsd EX-101.SCH 3054
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rnaz-20240403_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rnaz-20240403_pre.xml EX-101.PRE 22385
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2411028d1_8k_htm.xml XML 3795
Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Filer) CIK: 0001829635 (see all company filings)

EIN.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40363 | Film No.: 24827161
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)